Contact Us

Global Respiratory Syncytial Virus Vaccine Growth Analysis 2025, Forecast To 2044

11 Mar, 2025

What Is The Current and Historic Market Size Analysis Of The Respiratory Syncytial Virus Vaccine Market?

The respiratory syncytial virus vaccine market has seen considerable growth due to a variety of factors.
• In recent times, there has been robust growth in the market size of the respiratory syncytial virus vaccine. The market is expected to grow from $1280.23 million in 2024 to $1378.59 million in 2025, at a compound annual growth rate (CAGR) of 7.7%.
The exceptional growth during the historic period can be credited to factors such as the escalating RSV burden, initiatives from the government and WHO, heightened awareness about healthcare, and increased hospitalization rates.

What Are The Predictions for The Respiratory Syncytial Virus Vaccine Market in the Coming Years?

The respiratory syncytial virus vaccine market is expected to maintain its strong growth trajectory in upcoming years.
• The market for the respiratory syncytial virus vaccine is predicted to witness significant expansion in the coming years. The market is set to escalate to a robust $1828.41 million in 2029 with a compound annual growth rate (CAGR) of 7.3%.
The growth during the projected period can be traced back to the launch of approved vaccines, worldwide immunization initiatives, an increasing older population, and an expanding healthcare infrastructure. The future trends encompass technological progress, digital surveillance instruments, tailored vaccines, the creation of combined vaccines, and the innovation of adjuvants.

Which Drivers Are Accelerating Growth In The Respiratory Syncytial Virus Vaccine Market?

The increasing prevalence of respiratory diseases is anticipated to drive the expansion of the respiratory syncytial virus vaccine market in the future. Respiratory infections, triggered by viruses, bacteria, or other pathogens, impact the respiratory tract, including airways, sinuses, throat, or lungs. Factors such as air pollution, aging populations, climate change, accelerated urbanization, and the emergence of drug-resistant pathogens contribute to the upsurge of such infections. The vaccine for respiratory syncytial virus (RSV) assists in reducing these infections incidents by safeguarding against RSV-related diseases, predominantly affecting susceptible groups like infants and the elderly. For instance, the UK Health Security Agency reported in October 2024 that England observed a 10.7% annual increase in tuberculosis (TB) cases in 2023, elevating from 4,380 cases to 4,850 cases as compared to 2022. Consequently, the increasing prevalence of respiratory infections is expected to fuel the expansion of the respiratory syncytial virus vaccine market.

What Are The Core Segments Of The Global Respiratory Syncytial Virus Vaccine Market?

The respiratory syncytial virus vaccine market covered in this report is segmented –
1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine
2) By Clinical Indications: Pediatric Indication, Geriatric Indication, High-Risk Individuals
3) By Distribution Channel: Hospital And Others Pharmacies, Government Suppliers

Pre-Book The Respiratory Syncytial Virus Vaccine Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:

Which Emerging Market Trends Are Altering The Respiratory Syncytial Virus Vaccine Industry?

The prevailing trend in the Respiratory Syncytial Virus (RSV) vaccine market is a heightened emphasis on vaccine technology innovation, with a particular attention given to recombinant protein-based technology, as a means of maintaining relevance in the market. This technology involves genetic engineering to produce proteins that provoke an immune response, forming the basis for vaccines. Highlighting this was a significant development in May 2023, when UK-based pharmaceutical firm, GlaxoSmithKline plc, received approval from the U.S. Food and Drug Administration (FDA) for their Respiratory Syncytial Virus (RSV) vaccine named Arexvy. This vaccine, developed specifically for the prevention of lower respiratory tract disease caused by RSV in people aged 60 and older, uses cutting-edge recombinant protein-based technology. It targets the RSV fusion (F) protein, a key element in the virus’s ability to infect human cells.

Who Are the Key Players In The Respiratory Syncytial Virus Vaccine Market?

Major companies operating in the respiratory syncytial virus vaccine market include:
• Pfizer Inc.
• GlaxoSmithKline plc
• Moderna Inc.

What Are The Regional Insights Into The Respiratory Syncytial Virus Vaccine Market?

North America was the largest region in the respiratory syncytial virus vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.